Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Unione Europea - italiano - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus antigeni di superficie (emoagglutinina e neuraminidasi) del ceppo a/vietnam/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccini - immunizzazione attiva contro il sottotipo h5n1 del virus dell'influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Unione Europea - italiano - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccini - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus Unione Europea - italiano - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccini - active immunisation against h5 subtype of influenza a virus.

Jcovden (previously COVID-19 Vaccine Janssen) Unione Europea - italiano - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccini - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.

COVID-19 Vaccine Janssen Sospensione iniettabile Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

covid-19 vaccine janssen sospensione iniettabile

janssen-cilag ag - ad26.cov2-s - sospensione iniettabile - suspension: ad26.cov2-s 8,92 log10 infekt. einheiten, hydroxypropylbetadexum, acidum citricum monohydricum, 1-(4-tolyl)-ethanolum, acidum hydrochloridum, polysorbatum 80, natrii chloridum, natrii hydroxidum, trinatrii citras dihydricus, aqua ad iniectabile, pro dosi. - covid-19 vaccine janssen ist indiziert für die aktive immunisierung von personen im alter von 18 jahren und älter zur prävention der durch das sars-cov-2 verursachten covid-19-erkrankung - vaccini

Focetria Unione Europea - italiano - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - vaccini contro l'influenza - profilassi dell'influenza causata dal virus a (h1n1v) 2009. focetria dovrebbe essere usato in conformità con le linee guida ufficiali.

MS-H Vaccine Unione Europea - italiano - EMA (European Medicines Agency)

ms-h vaccine

pharmsure veterinary products europe ltd - mycoplasma synoviae ceppo ms-h - prodotti immunologici per uccelli, vaccini vivi batterica - pollo - per l'immunizzazione attiva dei futuri allevamento di polli da carne polli, futuro strato allevatore di polli e futuro strato di polli per ridurre l'aria sac lesioni e ridurre il numero di uova con anormale shell formazione causata da mycoplasma synoviae.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Unione Europea - italiano - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - virus dell'influenza reassortante (vivo attenuato) del seguente ceppo: ceppo a / vietnam / 1203/2004 (h5n1) - influenza, umano - vaccini - profilassi dell'influenza in una situazione pandemica ufficialmente dichiarata in bambini e adolescenti da 12 mesi a meno di 18 anni. pandemic influenza vaccine h5n1 astrazeneca dovrebbe essere usato in conformità con le linee guida ufficiali.

Pandemic Influenza Vaccine H5N1 Baxter AG Unione Europea - italiano - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - vaccino influenzale (intero virione, inattivato) contenente antigene di: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vaccini - profilassi dell'influenza in una situazione pandemica ufficialmente dichiarata. il vaccino contro l'influenza pandemica deve essere usato secondo le indicazioni ufficiali.

Spikevax (previously COVID-19 Vaccine Moderna) Unione Europea - italiano - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.